



Brent Penny,

J-9, Innovative Joint Medical R&D

Industry Day Exchange, Spring 2019

Defense Health Agency Industry Day Exchange June 04, 2019



J-9

Deputy Assistant Director, Research & Development (DAD, R&D)



- NDAA 2019 Section 711 directs NLT September 30, 2022, the Secretary of Defense shall, acting through the Director of the DHA, establish within the DHA, a subordinate organization to be called the DHA Research and Development.
 - Led, at the election of the Director, by a director or commander;
 - Comprised of the USAMRMC and such other medical research organizations and activities of the armed forces as the Secretary considers appropriate; and
 - Responsible for coordinating funding for DHP RDT&E, Congressionally Directed Medical Research Program (CDMRP); and related DoD medical research.

J-9

Deputy Assistant Director, Research & Development (DAD, R&D)



- Create a single research portfolio management process that:
 - ❑ Aligns RDT&E funded projects to operational gaps
 - ❑ Develops transparent programming that reduces redundancy
 - ❑ Ensures financial accountability through active management of portfolio assets

J-9

Deputy Assistant Director, Research & Development (DAD, R&D)



- Prior to National Defense Authorization Act for Fiscal Year 2019, Section 702:
 - Four separate systems of programmatic oversight
 - Inconsistent performance metrics collection and analysis
 - 12 Institutional Review Boards (IRB) functioning independently across four Components
 - No centralized priorities for CIP Medical Treatment Facilities research across the MHS

J-9

Deputy Assistant Director, Research & Development (DAD, R&D)



Sec. 711: Support to Working Group

DHP RDT&E Strategic Management Process Development

Human Research Protection Program and Clinical Investigation Program Transition to J-9

Responding to Change

“Medically Ready Force...Ready Medical Force”

For Official Use Only (FOUO)

J-9

Deputy Assistant Director, Research & Development (DAD, R&D)



- Developed detailed process flows
- Drafting guidebook to support research portfolio management processes
- Planning to conduct a Table Top Exercise
- Developing and coordinating separate HRPP and CIP DHA-Procedural Instructions for MTFs to operate under a single policy
 - Metrics consistent across the MHS
- Planning to stand-up a CIP Office that will combine the Services and DHA CIPs into a single DHA enterprise-wide program

J-9**Deputy Assistant Director, Research & Development (DAD, R&D)**

Champion for the M-2 strategic goal – Enhance Value Through Strategic Partnerships

- The National Defense Authorization Act of 2017 (NDAA FY17) directs the establishment of an integrated health delivery system through partnerships (Sec. 706) and a program to enhance the evaluation and treatment of veterans and civilians at MTFs (Sec 717). NDAA FY19 directs improvements to Trauma Center partnerships (Sec. 719).
- To meet these requirements, the DHA requires visibility and coordination of its partnerships and alliances, particularly its strategic partnerships and alliances (SPAs).

J-9

Deputy Assistant Director, Research & Development (DAD, R&D)



- Significant increase of responsibility
- Our responses are in development
 - Pending decisions by higher authorities and potentially NDAA2020

J-9

Deputy Assistant Director, Research & Development (DAD, R&D)



Specifications	Summary
Requiring Activity	<ul style="list-style-type: none">•
Opportunity Title	<ul style="list-style-type: none">•
Opportunity Description	<ul style="list-style-type: none">• <p>Development In Progress</p>